CN114041456A - Clinical-grade NK cell cryopreservation liquid and using method thereof - Google Patents
Clinical-grade NK cell cryopreservation liquid and using method thereof Download PDFInfo
- Publication number
- CN114041456A CN114041456A CN202111497839.7A CN202111497839A CN114041456A CN 114041456 A CN114041456 A CN 114041456A CN 202111497839 A CN202111497839 A CN 202111497839A CN 114041456 A CN114041456 A CN 114041456A
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- grade
- clinical
- cryopreservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 144
- 238000005138 cryopreservation Methods 0.000 title claims abstract description 96
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000007788 liquid Substances 0.000 title abstract description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 80
- 108010088751 Albumins Proteins 0.000 claims abstract description 21
- 102000009027 Albumins Human genes 0.000 claims abstract description 21
- 239000007924 injection Substances 0.000 claims abstract description 15
- 238000002347 injection Methods 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 147
- 239000000243 solution Substances 0.000 claims description 71
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 52
- 239000008354 sodium chloride injection Substances 0.000 claims description 42
- 229920002307 Dextran Polymers 0.000 claims description 39
- 239000002577 cryoprotective agent Substances 0.000 claims description 39
- 238000002156 mixing Methods 0.000 claims description 15
- 229940119744 dextran 40 Drugs 0.000 claims description 13
- 230000003204 osmotic effect Effects 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 claims description 9
- 229940119743 dextran 70 Drugs 0.000 claims description 9
- 239000003761 preservation solution Substances 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000011550 stock solution Substances 0.000 abstract description 62
- 238000011084 recovery Methods 0.000 abstract description 61
- 238000002360 preparation method Methods 0.000 abstract description 15
- 238000003860 storage Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000007710 freezing Methods 0.000 description 30
- 230000008014 freezing Effects 0.000 description 30
- 230000004083 survival effect Effects 0.000 description 30
- 210000004881 tumor cell Anatomy 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000010257 thawing Methods 0.000 description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229960002086 dextran Drugs 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a clinical-grade NK cell cryopreservation liquid and a using method thereof, and belongs to the technical field of NK cell cryopreservation and recovery. The components contained in the clinical-grade NK cell frozen stock solution are all injection grade or clinical grade, and can be directly infused into a human body. In addition, the invention reduces the dosage of injection-grade albumin and DMSO, reduces the preparation cost so as to be suitable for mass production, and provides conditions for storage and clinical application of clinical-grade NK cells.
Description
Technical Field
The invention relates to the technical field of NK cell cryopreservation and resuscitation, and particularly relates to a clinical-grade NK cell cryopreservation solution and a using method thereof.
Background
NK cells generally refer to natural killer cells (NK), are important immune cells of the body, are not only related to tumor resistance, virus infection resistance and immune regulation, but also participate in the occurrence of hypersensitivity and autoimmune diseases under certain conditions, and can recognize target cells and killing media. Common NK cells include NK cells derived from peripheral blood, NK cells derived from cord blood, NK cells derived from hPSC, and the like.
In recent years, NK cells have been used for cell therapy of tumor immunity and have a good effect in clinical treatment of tumors (such as leukemia, lymphoma and melanoma); however, the long-term efficient storage of NK cells is always a problem, both for third party cell banks and for clinical administration of delivery and application. The prior art mainly preserves the activity and function of NK cells by cryopreservation.
The prior NK cell frozen stock solution has various formulas. For example, chinese patent CN202010240894.7 discloses a NK cell cryopreservation solution, the cryopreservation solution formula comprises dextran, polylysine (CPLL) and basal medium, wherein CPLL is prepared from reagent grade succinic anhydride and epsilon-polylysine solution, the preparation process is complex, batch-to-batch differences are easy to occur, and CPLL and basal medium are reagent grade and cannot be used for clinical and direct infusion. Chinese patent CN201510727721.7 discloses a frozen stock solution of cultured NK cells, which contains tea polyphenols, grape seed extract, vitamin C and autologous serum, wherein the tea polyphenols, grape seed extract and vitamin C are not clinical grade components and the components of the extract are not clear, and can not be used for clinical and direct infusion. Chinese patent CN201910274568.5 discloses a cryopreservation method of NK cells, wherein the cryopreservation liquid is added with AB plasma and 5-glutenin-3-ol to improve the activity of the cells after cryopreservation recovery. The AB plasma has undefined components and different batches, and is not suitable for large-scale and standardized production and preparation; 5-glutenin-3-ol is a non-clinical grade component and cannot be used for clinical and direct infusion. In summary, the cryopreservation solution disclosed in the prior art can only be used for preservation of scientific research-grade products, but cannot be used for clinical injection.
Disclosure of Invention
In view of the above, the invention aims to provide a clinical-grade NK cell frozen stock solution, and the components of the clinical-grade NK cell frozen stock solution are injection-grade and clinical-grade medicines, and can be used for clinical injection.
The invention provides a clinical-grade NK cell frozen stock solution, which comprises a first frozen stock solution and a second frozen stock solution;
the first cryopreservation liquid comprises clinical grade basic cryopreservation liquid and an impermeable cryoprotectant; the mass concentration of the non-permeable cryoprotectant in the first frozen stock solution is less than or equal to 10 percent;
the second frozen stock solution comprises clinical grade basic frozen stock solution, an impermeable cryoprotectant and a permeable cryoprotectant; the mass concentration of the non-permeable cryoprotectant in the second frozen stock solution is less than or equal to 10 percent; the mass concentration of the permeable cryoprotectant in the second freezing solution is less than or equal to 20 percent;
the clinical grade basic freezing solution comprises dextran sodium chloride injection;
the non-osmotic cryoprotectant comprises injection grade albumin;
the osmotic cryoprotectant comprises injection grade DMSO.
Preferably, the dextran sodium chloride injection comprises dextran sodium chloride injection with a mass concentration of 10% or dextran sodium chloride injection with a mass concentration of 6%.
Preferably, the dextran sodium chloride injection is selected from one or more of dextran 40 sodium chloride injection, dextran 70 sodium chloride injection or dextran 20 sodium chloride injection.
Preferably, the mass concentration of the non-permeable cryoprotectant in the first frozen stock solution and the second frozen stock solution is independently 1-10%.
Preferably, the mass concentration of the osmotic cryoprotectant in the second frozen stock solution is 2 to 20 percent.
The invention also provides application of the clinical-grade NK cell cryopreservation liquid in the scheme in NK cell cryopreservation and/or iNK cell cryopreservation.
The invention also provides a use method of the clinical NK cell frozen stock solution, which comprises the following steps:
and mixing the NK cells and/or iNK cells to be cryopreserved, the first cryopreserving liquid and the second cryopreserving liquid, and then carrying out sectional cooling, wherein the cryopreserving is carried out after the sectional cooling.
Preferably, the mixing of the NK cells and/or iNK cells to be cryopreserved, the first cryopreservation solution and the second cryopreservation solution is that the NK cells and/or iNK cells to be cryopreserved are mixed with the first cryopreservation solution and then are mixed with the second cryopreservation solution.
Preferably, the final freezing density of the NK cells and/or iNK cells to be frozen is 1-8 x 107/mL。
Preferably, the volume ratio of the first frozen stock solution to the second frozen stock solution is (1-2): (1-2).
The invention provides a clinical-grade NK cell frozen stock solution, which comprises a first frozen stock solution and a second frozen stock solution; the first cryopreservation liquid comprises clinical grade basic cryopreservation liquid and an impermeable cryoprotectant; the mass concentration of the non-permeable cryoprotectant in the first frozen stock solution is less than or equal to 10 percent; the second frozen stock solution comprises clinical grade basic frozen stock solution, an impermeable cryoprotectant and a permeable cryoprotectant; the mass concentration of the non-permeable cryoprotectant in the second frozen stock solution is less than or equal to 10 percent; the mass concentration of the permeable cryoprotectant in the second freezing solution is less than or equal to 20 percent; the clinical grade basic freezing solution comprises dextran sodium chloride injection; the non-osmotic cryoprotectant comprises injection grade albumin; the osmotic cryoprotectant comprises injection grade DMSO. The components contained in the clinical-grade NK cell frozen stock solution are all injection grade or clinical grade, and can be directly infused into a human body. In addition, the invention reduces the dosage of injection-grade albumin and DMSO, reduces the preparation cost so as to be suitable for mass production, and provides conditions for storage and clinical application of clinical-grade NK cells. The cells frozen by the clinical-grade NK cell frozen stock solution can be directly infused into a human body, so that the clinical application of NK cell products is greatly promoted, the safety and the stability of clinical application of NK cell preparations can be improved, the pollution risk caused by operations such as centrifugal resuspension after cell resuscitation and the like can be avoided, the damage of the cells and the quality difference before infusion caused by the damage of the cells can be avoided, and the threshold of clinical application of the cell products can be reduced. The vicinity of the clinical infusion point does not need to be equipped with sterile operating facilities and experienced operators.
Secondly, the clinical-grade NK cell cryopreservation protective solution can maintain high survival rate and high recovery rate of the recovered NK cells and maintain the function of the NK cells in cracking tumor cells. The cell preparation prepared by the frozen stock solution has high stability after recovery, can maintain the cell survival rate and the recovery rate for a long time (8 hours) higher than 90 percent under the condition of high cell density and different temperatures, and ensures the stability of the cell preparation in clinical application.
In addition, the NK cell frozen stock solution provided by the invention reduces the use concentration of DMSO (dimethyl sulfoxide), and can avoid or reduce adverse reactions of a patient caused by infusion of a large amount of DMSO. DMSO is infused into a patient in a large amount in a short time, which is easy to cause adverse reactions, and has main systemic side reactions: headache, nausea, dizziness, and in patients who are secondarily sensitive to DMSO, respiratory disturbance and mild cardiotoxicity, hypertension or bradycardia occur, so that lowering the DMSO content in the clinically injected cells can reduce adverse reactions caused by cell infusion. Meanwhile, DMSO has certain toxic and side effects on cells at normal temperature, and the reduction of the content of DMSO is beneficial to the maintenance of the cell survival rate and functions after recovery. In addition, the common frozen stock solution has the problems of great cell loss, cell viability, proliferation capacity and differentiation capacity reduction caused by the operation of centrifugally removing DMSO after cells need to be recovered, the content of DMSO in the frozen stock solution is reduced, the centrifugation step can be omitted, the operation can be simplified, the subsequent cell differentiation and proliferation are facilitated, and the problems of pollution and the like in the production process of cell products are reduced.
Thirdly, the clinical-grade NK cell freezing solution has high freezing cell density, and the freezing final density of the NK cells to be frozen can reach 8-10 multiplied by 107and/mL. The clinical single infusion amount of NK cells is large, so that the cryopreserved high-density cell preparation has a plurality of benefits for clinical application, the storage and the transportation are convenient, the cryopreserved volume is reduced, the resuscitation time is shortened, the cell injury and the pollution risk can be avoided, and the infusion frequency of a tested body is reduced.
Finally, the NK cell cryopreservation liquid provided by the invention can be used for cryopreservation of not only primary NK cells but also iNK cells. iNK cells induced by iPSC have obvious clinical application advantages compared with primary NK cells, and the NK cell frozen stock solution provided by the invention can promote clinical application of the primary NK cells and iNK cells.
Drawings
FIG. 1 is a flow chart of the cryopreservation and resuscitation of NK cells in the present invention;
FIG. 2 recovery rate and recovery rate of frozen stock solution after cryopreservation of NK cells;
FIG. 3 morphology of NK cells after 2 days of resuscitation;
FIG. 4 survival rate and recovery rate of NK cells after cryopreservation recovery under different proportions of albumin;
FIG. 5 survival rate and recovery rate of NK cells after cryopreservation recovery under different cryopreservation densities of the cells;
FIG. 6 survival and recovery of NK cells after cryopreservation recovery at different DMSO concentrations;
FIG. 7 CD56+/CD 3-expression of NK cryopreserved cells and fresh cells;
FIG. 8 expression of surface marker receptors of NK cryopreserved cells and fresh cells;
FIG. 9 cell viability after recovery of NK cells (preservation in frozen stock solution for a certain time after recovery);
FIG. 10 recovery rate after recovery of NK cells (preservation in frozen stock solution for a certain time after recovery);
FIG. 11 tumor cell lysis capacity after NK cell recovery (after 8 hours of preservation in frozen stock solution after recovery);
FIG. 12 shows that NK cryopreservation solution has cryopreservation protection effect on primary NK cells;
FIG. 13 lytic capacity of NK cryopreserved cells and fresh cells on different tumor cells;
FIG. 14NK cryopreserved cells can significantly inhibit the proliferation of tumor cells in K562 mouse tumor model.
Detailed Description
The invention provides a clinical-grade NK cell frozen stock solution, which comprises a first frozen stock solution and a second frozen stock solution;
the first cryopreservation liquid comprises clinical grade basic cryopreservation liquid and an impermeable cryoprotectant; the mass concentration of the non-permeable cryoprotectant in the first frozen stock solution is less than or equal to 10 percent; the second frozen stock solution comprises clinical grade basic frozen stock solution, an impermeable cryoprotectant and a permeable cryoprotectant; the mass concentration of the non-permeable cryoprotectant in the second frozen stock solution is less than or equal to 10 percent; the mass concentration of the permeable cryoprotectant in the second freezing solution is less than or equal to 20 percent;
the clinical grade basic freezing solution comprises dextran sodium chloride injection;
the non-osmotic cryoprotectant comprises injection grade albumin;
the osmotic cryoprotectant comprises injection grade DMSO.
In the present invention, the dextran sodium chloride injection preferably includes dextran 40 sodium chloride injection, dextran 70 sodium chloride injection or dextran 20 sodium chloride injection.
In the invention, the dextran sodium chloride injection preferably comprises dextran sodium chloride injection with the mass concentration of 10% or dextran sodium chloride injection with the mass concentration of 6%. In the invention, the mass concentration of sodium chloride in the dextran sodium chloride injection is preferably 0.9%. In the present invention, the mass concentration of the impermeable cryoprotectant in the first frozen stock solution and the second frozen stock solution is independently preferably 1% to 10%, and more preferably 3% to 8%.
In the present invention, the mass concentration of the osmotic cryoprotectant in the second cryopreservation solution is preferably 2% to 20%, more preferably 3% to 16%, even more preferably 4% to 10%, and most preferably 5% to 8%.
The source of the injection-grade albumin is not particularly limited in the invention, and commercially available clinical albumin can be used.
The source of the injection-grade DMSO is not particularly limited in the invention, and the injection-grade DMSO sold in the market can be used.
In the invention, the dextran sodium chloride injection is from conventional market. The dextran sodium chloride injection is not limited to the above, and other dextran sodium chloride injections which can be used in clinical grade can be included. Wherein the dextran can be selected from dextran 70, dextran 40 and dextran 20, i.e. the dextran sodium chloride injection can be selected from dextran 70, dextran 40 and dextran 20 sodium chloride injection. Further, the dextran sodium chloride injection may be selected from 10% or 6% dextran 70 or dextran 40 or dextran 20 sodium chloride injection. Such as: 6% dextran 20 sodium chloride injection: 500ml of dextran 20 30g and sodium chloride 4.5 g; 6% dextran 40 sodium chloride injection: 500ml, 30g of dextran 40 and 4.5g of sodium chloride and the like.
In the invention, the dextran sodium chloride injection contains dextran which belongs to macromolecular saccharides and has a freezing protection effect on cells, and the dextran partially replaces the freezing protection function of DMSO (dimethyl sulfoxide), so that the concentration of the DMSO can be greatly reduced. In addition, the dextran has the functions of protecting and promoting the survival of NK cells, and the great reduction of the concentration of the DMSO can reduce the damage to the cryopreserved cells, so that the clinical-grade cell cryopreservation solution can improve the stability of the cryopreserved cells.
The invention also provides application of the clinical-grade NK cell cryopreservation liquid in the scheme in NK cell cryopreservation and/or iNK cell cryopreservation.
The invention has no special limitation on the source and preparation method of the NK cells and iNK cells, and in the specific implementation process of the invention, the NK cells are preferably derived from peripheral blood or umbilical cord blood, and can be isolated, cultured and amplified by adopting the conventional technical means in the field; said iNK is preferably obtained by hPSC (pluripotent stem cell) differentiation, and the method of differentiation is preferably the method disclosed in Chinese patent CN202010153358.3 for differentiating human pluripotent stem cells into natural killer cells.
The invention also provides a use method of the clinical NK cell frozen stock solution, which comprises the following steps:
and mixing the NK cells and/or iNK cells to be cryopreserved, the first cryopreserving liquid and the second cryopreserving liquid, and then carrying out sectional cooling, wherein the cryopreserving is carried out after the sectional cooling.
In the present invention, the NK cells and/or iNK cells to be cryopreserved, the first cryopreservation solution and the second cryopreservation solution are mixed in the order of mixing the NK cells and/or iNK cells to be cryopreserved with the first cryopreservation solution and then mixing with the second cryopreservation solution. The mixing sequence can improve the survival rate and the recovery rate of the cells after the cryopreservation recovery
In the present invention, the second cryopreservation solution is preferably added dropwise to a mixed system of the NK cells and/or iNK cells to be cryopreserved and the first cryopreservation solution.
In the invention, the freezing final density of the NK cells and/or iNK cells to be frozen is preferably 1-8 x 107A volume of 5 to 8X 10 is more preferable7/mL。
In the present invention, the volume ratio of the first frozen stock solution to the second frozen stock solution is preferably (1-2): (1-2), more preferably 1: 1.
the sectional cooling procedure is not particularly limited, and the conventional freezing technology in the field can be adopted; the instrument adopted by the sectional cooling is preferably a program cooling instrument.
In the present invention, after the cryopreservation, it is preferable to further comprise thawing the cryopreserved cells; the thawing temperature is 36-39 ℃, and more preferably 37 ℃; the thawing time is 1-2 min, and the ice crystals in the cell suspension are taken out when the ice crystals are about to completely disappear through visual observation; the thawing mode is preferably water bath thawing.
In the present invention, the cryopreservation method is preferably performed in liquid nitrogen, and the frozen stock can be stored for a long time.
In the present invention, the revived cells can be used directly for injection.
The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention.
Reagents used in the following examples: 1. human serum albumin, Chengdu Rong drug industry, 20%, 10g/50 ml/bottle; 2. shijiazhuang four drugs, dextran 40 sodium chloride injection, 500ml, 30g dextran 40 and 4.5g sodium chloride; 3. Cryosure-DMSO (dimethyl sulfoxide) cryopreservation solution 70 ml/bottle, OriGenbiochemical company in the United states; 4. 500ml of dextran 20 and sodium chloride injection of Shandongdi pharmaceutical industry Co., Ltd, 30g of dextran 20 and 4.5g of sodium chloride; 5. 500ml of Zhejiang Tianrui dextran 70 sodium chloride injection: 30g dextran 70 and 4.5g sodium chloride.
Example 1NK cells cryopreservation and Resuscitation
The specific freezing operation process is shown in figure 1.
1. Preparing clinical NK cell frozen stock solution:
1) first frozen stock solution (frozen stock solution A)
Adding injection-grade albumin into 6% dextran 40 sodium chloride injection, slightly inverting and mixing, wherein the mass concentration of the injection-grade albumin in the frozen solution A is 3g/100mL, and storing in a refrigerator at 4 ℃ for later use.
2) Second frozen stock solution (frozen stock solution B)
Adding injection-grade albumin into 6% dextran 40 sodium chloride injection, slightly reversing the mixture from top to bottom, uniformly mixing the mixture, adding injection-grade DMSO, wherein the mass concentration of the injection-grade albumin in the frozen B solution is 3g/100mL, the mass concentration of the injection-grade DMSO in the frozen B solution is 6g/100mL, and storing the mixture in a refrigerator at 4 ℃ for later use.
2. NK cell cryopreservation
1) Treatment group a + B: collecting NK cells, washing the NK cells with a conventional salt solution and centrifuging; discarding supernatant, resuspending the cells with a certain volume of frozen solution A, mixing, counting cells, and adjusting cell density to 10 according to counting result8Per mL; slowly dripping the frozen B solution with the same volume, uniformly mixing, and subpackaging the cell suspension.
2) Group AB: mixing the frozen solution A and the frozen solution B in advance according to the volume ratio of 1:1 under the aseptic condition, subsequently adding NK cells (the final cell density is consistent with that in the A + B treatment group), uniformly mixing, and subpackaging the cell suspension.
3. Programmed cooling
And (3) putting the frozen and stored subpackage tubes into a program cooling instrument for sectional cooling, and immediately transferring the frozen and stored cells into liquid nitrogen after the program cooling is finished, so that the frozen and stored cells can be stored for a long time. If the programmed cooling conditions are as follows: programmed cooling-program (4-0 deg.C, -10 deg.C/min, holingat 0 deg.C, 15min, 0-8 deg.C, -1 deg.C/min, -8 deg.C-45 deg.C, -50 deg.C/min, -45 deg.C-12 deg.C, +15 deg.C/min, -12 deg.C-100 deg.C, -1 deg.C/min).
4. NK cell resuscitation
Preheating a water bath to 37 ℃, transferring the cells stored in the liquid nitrogen to cells by using a dry ice box, taking out the freezing tube, quickly placing the freezing tube in the water bath at 37 ℃, slightly shaking the freezing tube within 1-2 min, and taking out the freezing tube when the ice crystals in the cell suspension are about to completely disappear by visual observation.
After recovery, the survival rate and recovery rate of the cells (not washed) were directly tested, and the results are shown in FIG. 2, AB indicates group AB (solution A and solution B were mixed at a ratio of 1:1 before the cells were added), and A + B indicates group A + B (cells were resuspended in solution A first, and then solution B was added dropwise).
Experiments show that the survival rate and recovery rate of iNK cells (prepared by referring to iNK preparation method in CN 202010153358.3) are high and can reach more than 90% no matter what application mode. And the cells are treated by using a mode of firstly freezing the solution A and uniformly mixing the cells and then dripping the solution B, and the survival rate and the recovery rate of iNK cells are higher after freezing recovery, so that the method is a better freezing mode.
In other embodiments, the NK cells are cryopreserved and recovered by using dextran 70 or dextran 40 or dextran 20 sodium chloride injection with 10% or 6% according to the experimental processes and steps, wherein the mass concentration of injection-grade albumin is 4-6 g/100mL or the mass concentration of injection-grade DMSO in cryopreserved B liquid is 10-16 g/100mL, and it is found that the survival rate and recovery rate of iNK cells can reach more than 90% no matter what method is used, the difference from the above results is not great, and the method of uniformly mixing the cells by using the cryopreserved A liquid and then dropping the cryopreserved B liquid is more preferable.
Example 2: NK cells show typical aggregation growth form after 2 days of resuscitation
After thawing the cryopreserved NK cells in example 1, the cells were thawed at 1X 106After the cells are inoculated into a cell culture plate for suspension culture for 2 days, the cells form a typical NK cell clustering phenomenon, the clustering phenomenon indicates that the state and the activity of the cells are higher, and indicates that the cryopreservation protection effect of a cryopreservation solution on the NK cells is better, so that the cells can quickly recover the cell activity and the amplification capacity after recovery, and the result is shown in figure 3.
Example 3: influence of albumin concentration on survival rate and recovery rate of cryopreserved NK cells after resuscitation.
Freezing and storing NK cells, testing whether the addition and concentration of albumin can influence the survival rate and recovery rate of the recovered NK cells, and testing the concentration of albumin in a frozen storage solution to be 0, 1%, 3%, 5%, 8% and 10%, wherein the survival rate and recovery rate of the recovered cells are the cell survival rate/total cell number; the cell recovery rate is the number of viable cells after resuscitation/the number of viable cells before resuscitation, and the results are shown in fig. 4.
It can be seen that the albumin contained in the frozen stock solution can obviously improve the survival rate and the recovery rate of the cells after the frozen stock recovery. The concentration of albumin in the frozen stock solution is preferably 3% to 8%. Compared with the prior art, the albumin concentration is obviously reduced while the high recovery rate and the high survival rate of cells are maintained, and the cost of the frozen stock solution can be reduced. For large-scale production and clinical application, the total application amount of albumin can be greatly saved, so that the large-scale production cost is reduced.
Example 4: influence of cell cryopreservation density on survival rate and recovery rate of cryopreserved NK cells after recovery
Setting the cell density at 2X 10 for freezing NK6/mL、5×106/mL、1×107/mL、2×107/mL、5×107/mL、8×107/mL、10×107Performing cryopreservation test, and detecting the survival rate and recovery rate of the recovered NK cells, wherein the cell survival rate is the number of viable cells/the total number of the cells; cell recovery rate-number of viable cells after resuscitation/number of viable cells before resuscitation, and the results are shown in fig. 5.
Therefore, when the NK cells are frozen, the freezing density of the cells can reach 10 multiplied by 107A volume of 1 to 8X 107The best effect is 5-8 multiplied by 10 per mL7The viability and recovery rate of the/mL cell are better. Compared with the prior art, the density of the frozen cells can be obviously improved, and the clinical use is facilitated.
Example 5: influence of DMSO on survival and recovery rate after NK cell resuscitation.
When the cell freezing density is 5-8 multiplied by 107In the case of/mL, the final concentration of DMSO in the frozen stock is tested to be 0%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 20%, and the survival rate and recovery rate of the cells after recovery, wherein the cell survival rate is the number of viable cells/the total number of cells; the cell recovery rate is the number of viable cells after resuscitation/the number of viable cells before resuscitation, and the results are shown in fig. 6.
Therefore, when the cryopreservation density of NK cells is 5-8 multiplied by 107at/mL, the final concentration of DMSO can be reduced to 2-8% without affecting the survival rate and recovery rate of the cells after recovery. Compared with the prior art, the final concentration of DMSO is remarkably reduced, and clinical use is facilitated.
Example 6: after the NK cells are recovered, the cell survival rate and the recovery rate are higher, the purity can be still kept higher, and the expression of NK cell surface marker receptors is maintained.
The cryopreservation liquid and the corresponding program of the invention are used for cryopreservation of NK cells, and the cells still have higher cell survival rate and recovery rate after recovery. Further, identification and detection of specific markers (CD3 and CD56) are carried out on the recovered NK cells by a flow cytometry method; meanwhile, the expression of NK cell surface marker receptors is detected by a flow cytometry method (NKG2A and KIR are NK cell surface inhibitory receptors, and NKG2D and Nkp30 are NK cell surface activating receptors). Compared with fresh NK cells, the cryopreserved recovered NK cells in the invention still have higher purity (CD56+ CD3- > 95%) and maintain the expression of cell surface marker receptors, and the results are shown in FIG. 7 and FIG. 8.
Therefore, compared with the fresh cells which are not frozen, the NK cells frozen by using the freezing solution and the freezing method have higher purity after cell recovery, and the expression of important surface marker receptors of the cells is maintained.
Example 7: after the NK cells are recovered, the stability of the cell preparation can be maintained in a frozen stock solution.
Because the NK cells frozen by the frozen stock solution can be directly used for clinical infusion, the preparation stability of the cell preparation after recovery is tested. After recovering NK cells, respectively standing the recovered NK cells in the temperature environments of 37 ℃, room temperature (25-28 ℃) and 4 ℃ for a certain time, and taking the cells at different time points (0h, 2h, 4h, 6h and 8h) to detect the survival rate and the recovery rate of the cells, wherein the cell survival rate is the number of the living cells/the total number of the cells; the cell recovery rate is the number of viable cells after resuscitation/the number of viable cells before resuscitation, and the results are shown in fig. 9 and fig. 10. NK cells incubated in the frozen stock for 8h were compared to K562 tumor cells at an effective target ratio of 3: 1 co-culture for 24h, and testing the capability of killing tumor cells in vitro, wherein the result shows that the NK cells stored in the frozen stock solution can maintain the tumor cell lysis function, and the result is shown in figure 11.
As can be seen, after the NK cells are recovered, the stability of the NK cell preparation can be maintained for at least 8 hours, the NK cell preparation can adapt to different temperature environments, the cell survival rate can be maintained to be more than 90%, the cell recovery rate is more than 90%, and the function of the NK cells in tumor cell lysis can be maintained.
Example 8: the NK frozen stock solution has the freezing preservation protection effect on primary NK cells (PBNK cells derived from peripheral blood and CBNK cells derived from umbilical cord blood).
Extracting mononuclear cells from peripheral blood or umbilical cord blood, enriching by using CD56 antibody magnetic beads to obtain cells with the CD56 positive rate of more than 95%, activating and amplifying in a CD16 antibody and cytokine mode, or co-culturing and activating and amplifying by using trophoblasts expressing stimulating factors, amplifying for two weeks to obtain PBNK cells derived from the peripheral blood and CBNK cells derived from the umbilical cord blood, freezing the PBNK and the CBNK cells by using the frozen stock solution, detecting the cell viability and the recovery rate after recovery, wherein the cell viability is the viable cell number/the total cell number; the cell recovery rate is the number of viable cells after resuscitation/the number of viable cells before resuscitation, and the results are shown in fig. 12. Recovered PBNK and CBNK cells were compared to K562 tumor cells at an effective target ratio of 3: 1 co-culture for 24h, testing the capability of killing tumor cells in vitro, and showing that the expanded PBNK and CBNK cells can be preserved in the frozen stock solution of the invention and maintain the tumor cell lysis function, and the result is shown in figure 12.
The NK cryopreservation solution can be simultaneously used for cryopreservation of primary NK cells and iNK cells.
Example 9: the frozen NK cells can crack various tumor cell strains, and have similar function with the fresh NK cells. Meanwhile, the recovered NK cells are directly injected into a K562 mouse tumor model by tail vein injection, and the proliferation of tumor cells in a mouse body can be obviously inhibited.
Cryopreserved NK cells were recovered immediately after resuscitating at an effective target ratio of 3: 1 co-culturing for 24H, and testing the capability of killing tumor cells in vitro, wherein MOML13, NB4 and Kasumi-1 are human acute myelocytic leukemia cell strains, K562 and KU812 are human chronic myelocytic leukemia cell strains, Raji is a human lymphoma cell strain, A549 and H460 are human lung cancer cell strains, Huh7 is a human hepatoma cell strain, SKOV-3 is a human ovarian cancer cell strain, and SKMEL-2 is a human melanoma cell strain. The results show that the cryopreserved NK cells can maintain the lysis function of different tumor cells, and the results are shown in FIG. 13.
And (3) injecting the cryopreserved NK cells into a K562 mouse tumor model in tail vein immediately after recovery, injecting the cryopreserved recovered NK cells one day after inoculating the tumor cells, and detecting tumor cell signals in the mouse body by using a living body imaging instrument on the 21 st day after inoculating the tumor cells. The results show that cryopreserved NK cells can inhibit proliferation of K562 tumor cells in tumor model mice, and the results are shown in fig. 14.
After the cryopreserved cells are recovered, the cryopreserved cells can directly kill various tumor cells cultured in vitro to different degrees, and can also be directly used for injection treatment of tumor-bearing mice, which shows that the NK cryopreservation solution disclosed by the invention has small damage to the NK cells and can maintain the tumor cell lysis function of the NK cells in vitro and in vivo. Compared with the prior art, the adverse effect of the cryopreservation recovery process on the activity and the function of the NK cells is reduced.
Although the present invention has been described in detail with reference to the above embodiments, it is only a part of the embodiments of the present invention, not all of the embodiments, and other embodiments can be obtained without inventive step according to the embodiments, and the embodiments are within the scope of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111497839.7A CN114041456B (en) | 2021-12-09 | 2021-12-09 | Clinical-grade NK cell cryopreservation liquid and using method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111497839.7A CN114041456B (en) | 2021-12-09 | 2021-12-09 | Clinical-grade NK cell cryopreservation liquid and using method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114041456A true CN114041456A (en) | 2022-02-15 |
| CN114041456B CN114041456B (en) | 2022-12-27 |
Family
ID=80212661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111497839.7A Active CN114041456B (en) | 2021-12-09 | 2021-12-09 | Clinical-grade NK cell cryopreservation liquid and using method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114041456B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115005199A (en) * | 2022-07-14 | 2022-09-06 | 北京鼎成肽源生物技术有限公司 | A kind of natural killer cell cryopreservation solution, cryopreservation method and application |
| CN115039764A (en) * | 2022-07-14 | 2022-09-13 | 北京鼎成肽源生物技术有限公司 | A method of cryopreservation of natural killer cells |
| CN116806813A (en) * | 2023-06-29 | 2023-09-29 | 吉林省拓华生物科技有限公司 | Cell cryopreservation protection liquid and cryopreservation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106665560A (en) * | 2017-01-16 | 2017-05-17 | 哈尔滨医科大学 | Direct venous re-transfusion immune cell cryopreservation medium and application thereof |
| CN108142412A (en) * | 2017-12-27 | 2018-06-12 | 重庆斯德姆生物技术有限公司 | A kind of immunocyte frozen stock solution and cryopreservation methods |
| CN110024775A (en) * | 2019-05-10 | 2019-07-19 | 友康恒业生物科技（北京）有限公司 | The clinical cytology preparation formula and purposes for saving liquid |
| CN111248192A (en) * | 2020-03-31 | 2020-06-09 | 青岛麦迪赛斯医疗技术有限公司 | A kind of NK cell cryopreservation solution |
| CN111387174A (en) * | 2020-01-17 | 2020-07-10 | 广东先康达生物科技有限公司 | Immune cell cryopreservation solution and immune cell cryopreservation method |
| CN112400863A (en) * | 2020-11-26 | 2021-02-26 | 成都康景生物科技有限公司 | Clinical NK cell cryopreservation liquid and cryopreservation method |
| CN113061576A (en) * | 2021-02-24 | 2021-07-02 | 河南省银丰生物工程技术有限公司 | Immune cell NK frozen stock solution and activity research method thereof |
-
2021
- 2021-12-09 CN CN202111497839.7A patent/CN114041456B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106665560A (en) * | 2017-01-16 | 2017-05-17 | 哈尔滨医科大学 | Direct venous re-transfusion immune cell cryopreservation medium and application thereof |
| CN108142412A (en) * | 2017-12-27 | 2018-06-12 | 重庆斯德姆生物技术有限公司 | A kind of immunocyte frozen stock solution and cryopreservation methods |
| CN110024775A (en) * | 2019-05-10 | 2019-07-19 | 友康恒业生物科技（北京）有限公司 | The clinical cytology preparation formula and purposes for saving liquid |
| CN111387174A (en) * | 2020-01-17 | 2020-07-10 | 广东先康达生物科技有限公司 | Immune cell cryopreservation solution and immune cell cryopreservation method |
| CN111248192A (en) * | 2020-03-31 | 2020-06-09 | 青岛麦迪赛斯医疗技术有限公司 | A kind of NK cell cryopreservation solution |
| CN112400863A (en) * | 2020-11-26 | 2021-02-26 | 成都康景生物科技有限公司 | Clinical NK cell cryopreservation liquid and cryopreservation method |
| CN113061576A (en) * | 2021-02-24 | 2021-07-02 | 河南省银丰生物工程技术有限公司 | Immune cell NK frozen stock solution and activity research method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115005199A (en) * | 2022-07-14 | 2022-09-06 | 北京鼎成肽源生物技术有限公司 | A kind of natural killer cell cryopreservation solution, cryopreservation method and application |
| CN115039764A (en) * | 2022-07-14 | 2022-09-13 | 北京鼎成肽源生物技术有限公司 | A method of cryopreservation of natural killer cells |
| CN115005199B (en) * | 2022-07-14 | 2023-08-22 | 北京鼎成肽源生物技术有限公司 | Freezing solution, freezing method and application of natural killer cells |
| CN115039764B (en) * | 2022-07-14 | 2024-03-12 | 北京鼎成肽源生物技术有限公司 | Freezing method of natural killer cells |
| CN116806813A (en) * | 2023-06-29 | 2023-09-29 | 吉林省拓华生物科技有限公司 | Cell cryopreservation protection liquid and cryopreservation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114041456B (en) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114041456A (en) | Clinical-grade NK cell cryopreservation liquid and using method thereof | |
| CN105076116B (en) | A kind of cells frozen storing liquid and its application and the cryopreservation methods of megakaryoblast | |
| Muckle et al. | The selective inhibitory effect of hyperthermia on the metabolism and growth of malignant cells | |
| JP3165863B2 (en) | Cryopreservation solution | |
| US8198085B2 (en) | Somatic cells for use in cell therapy | |
| CN103563888A (en) | Cell freezing medium | |
| CN104719282A (en) | Peripheral blood mononuclear cell serum-free freezing medium and freezing method | |
| KR102233660B1 (en) | Effective NK cell culture methods with NK Cell Culture Media Kit | |
| CN106701681A (en) | In vitro induction amplification, freeze preservation and anabiosis method of immune cells | |
| CN107771780A (en) | CAR-T cell cryopreservation medium and cryopreservation method | |
| US20210238549A1 (en) | Use of memory lymphocyte population in liver cancer treatment | |
| CN112998009A (en) | NK cell cryopreservation liquid and preparation method and application thereof | |
| CN115005199B (en) | Freezing solution, freezing method and application of natural killer cells | |
| CN106967675A (en) | A kind of method of the separation and Extraction candidate stem cell from placenta | |
| CN105211052B (en) | Frozen stock solution of cultured NKT cells and preparation method thereof | |
| CN116998475A (en) | A tissue preservation solution for preservation and transportation of fresh tumor tissue and its application | |
| CN108142412A (en) | A kind of immunocyte frozen stock solution and cryopreservation methods | |
| CN112779217A (en) | Method for culturing high memory phenotype tumor infiltrating T lymphocytes | |
| CN104222069A (en) | Erythroid progenitor cell cryopreservation liquid and application thereof | |
| CN105754939A (en) | Method for improving directional differentiation effects on erythroid progenitor cells in umbilical cord blood | |
| JP2013233102A (en) | Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation | |
| CN112167241A (en) | Stem cell freezing medium and stem cell freezing and recovering method | |
| US20230148586A1 (en) | Low-temperature storage of biological samples | |
| CN113854280A (en) | A novel cryopreservation solution and its preparation method and application | |
| CN110679588A (en) | Chimeric antigen receptor T cell cryopreservation medium and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |